On September 10, 2020 DURECT Corporation (Nasdaq: DRRX) reported that it will participate in the HC Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Press release, DURECT, SEP 10, 2020, https://investors.durect.com/news-releases/news-release-details/durect-corporation-participate-september-virtual-investor?field_nir_news_date_value[min]=2020 [SID1234564964]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HC Wainwright 22nd Annual Global Investment Conference
Date Monday, September 14
Time: 2:30-2:50 PM EDT (Fireside Chat with Ed Arce)
Webcast: View Source

Cantor Fitzgerald Virtual Global Healthcare Conference
Date Tuesday, September 15
Time 10-10:30am EDT (Fireside Chat with Ellie Merle)
Webcast: View Source

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 22
Time: 11:40am-12:20pm EDT (Fireside chat with Francois Brisebois)
Webcast: View Source

On September 10, 2020 MaxCyte, a global cell-based therapies and life sciences company, reported that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020 (Press release, MaxCyte, SEP 10, 2020, View Source;co-22nd-annual-global-investment-virtual-conference-301125117.html [SID1234564980]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Date/Time: Monday, September 14, at 4:00 p.m. EDT
Online access: View Source

On September 10, 2020 Merck (NYSE: MRK), known as MSD outside the United States and Canada, reported that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate in a virtual fireside chat at the Morgan Stanley 18th Annual Conference on Sept. 15, 2020, at 9:30 a.m. EDT (Press release, Merck & Co, SEP 10, 2020, View Source [SID1234564929]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at View Source

On September 10, 2020 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4 (Press release, Bicycle Therapeutics, SEP 10, 2020, View Source [SID1234564948]). BT8009 is a second-generation BTC, which uses a valine-citrulline cleavable linker and a cytotoxin MMAE payload. It targets Nectin-4, which is a well-validated tumor antigen. Overexpression of Nectin-4 has been observed in several common tumor types and is associated with poor disease prognosis. The Phase I/II trial of BT8009 will be conducted in patients with advanced solid tumors associated with Nectin-4 expression.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"BT8009 is one of a new class of tumor-targeting agents that we believe represent the next generation of treatments for solid tumors. With a molecular weight 50-100 times smaller than that of a typical antibody drug conjugate, or ADC, and the anticipated ability to fully penetrate tumors with precision, we believe Bicycles may have significant advantages over antibody-based approaches to tumor antigen targeting, a hypothesis supported by results from our preclinical studies," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "In preclinical head-to-head comparisons with an ADC targeting Nectin-4, BT8009 demonstrated superior anti-tumor activity, including complete regressions of very large and small tumors across multiple xenograft models. Given BT8009’s potential utility, we plan to pursue a clinical development path that could enable us to bring this novel therapy to patients efficiently."

The Phase I/II multi-center, open-label trial will evaluate BT8009 administered once weekly. Enrollment is ongoing in the Phase I dose escalation of BT8009 given as a monotherapy, and the Company plans to evaluate BT8009 dosed in combination with an immune checkpoint inhibitor in future Phase I dose escalation cohorts. The Phase I portion of the trial is primarily designed to assess the safety and tolerability of BT8009, and to determine a recommended Phase II dose (RP2D). Following selection of an RP2D, Bicycle expects to initiate a Phase II dose expansion portion with the primary objective of evaluating the clinical activity of BT8009 in patients with Nectin-4-positive tumors.

On September 10, 2020 BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, reported that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thursday, September 17, 2020 at 11:45 a.m. ET (Press release, BeiGene, SEP 10, 2020, View Source/news-releases/news-release-details/beigene-present-morgan-stanley-18th-annual-global-healthcare" target="_blank" title="View Source/news-releases/news-release-details/beigene-present-morgan-stanley-18th-annual-global-healthcare" rel="nofollow">View Source [SID1234564965]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed from the investors section of BeiGene’s website at View Source or View Source An archived replay will be available following the event for 90 days.